Phase I Dose Escalation Study of Carboplatin, Pemetrexed and Exemestane in Post-menopausal Women With Metastatic Non-squamous NSCLC
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
At a glance
- Drugs Carboplatin (Primary) ; Exemestane (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 03 May 2019 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Planned End Date changed from 1 Aug 2015 to 30 Sep 2019.
- 12 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 30 Sep 2018.